Cetera Investment Advisers Increases Stock Position in Roivant Sciences Ltd. (NASDAQ:ROIV)

Cetera Investment Advisers increased its holdings in shares of Roivant Sciences Ltd. (NASDAQ:ROIV) by 39.4% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 100,288 shares of the company’s stock after purchasing an additional 28,324 shares during the period. Cetera Investment Advisers’ holdings in Roivant Sciences were worth $1,060,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also recently added to or reduced their stakes in the company. nVerses Capital LLC acquired a new stake in shares of Roivant Sciences in the 2nd quarter valued at about $34,000. Point72 Hong Kong Ltd acquired a new stake in shares of Roivant Sciences in the 2nd quarter valued at about $36,000. Quarry LP acquired a new stake in shares of Roivant Sciences in the 2nd quarter valued at about $53,000. Acadian Asset Management LLC acquired a new stake in shares of Roivant Sciences in the 1st quarter valued at about $72,000. Finally, Fifth Third Wealth Advisors LLC acquired a new stake in shares of Roivant Sciences in the 2nd quarter valued at about $101,000. 64.76% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on ROIV shares. Piper Sandler upped their target price on shares of Roivant Sciences from $20.00 to $22.00 and gave the company an “overweight” rating in a research note on Wednesday, July 10th. Bank of America boosted their price objective on shares of Roivant Sciences from $12.00 to $12.50 and gave the company a “neutral” rating in a research report on Wednesday, September 11th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Roivant Sciences in a research report on Thursday, September 19th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $18.00 price objective on shares of Roivant Sciences in a research report on Thursday, September 19th. One investment analyst has rated the stock with a hold rating and nine have given a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $17.39.

Insider Activity at Roivant Sciences

In other Roivant Sciences news, Director Financial Lp Qvt sold 876,000 shares of the stock in a transaction that occurred on Thursday, September 26th. The shares were sold at an average price of $11.82, for a total value of $10,354,320.00. Following the completion of the sale, the director now owns 22,179,358 shares in the company, valued at $262,160,011.56. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In related news, Director Financial Lp Qvt sold 876,000 shares of the firm’s stock in a transaction on Thursday, September 26th. The shares were sold at an average price of $11.82, for a total value of $10,354,320.00. Following the transaction, the director now directly owns 22,179,358 shares in the company, valued at approximately $262,160,011.56. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CEO Matthew Gline sold 1,983,257 shares of the firm’s stock in a transaction on Monday, September 23rd. The shares were sold at an average price of $11.79, for a total transaction of $23,382,600.03. Following the completion of the transaction, the chief executive officer now owns 17,870,543 shares in the company, valued at $210,693,701.97. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 3,477,309 shares of company stock worth $40,986,184. 4.60% of the stock is owned by corporate insiders.

Roivant Sciences Price Performance

NASDAQ ROIV opened at $11.91 on Friday. Roivant Sciences Ltd. has a 52 week low of $8.24 and a 52 week high of $13.06. The company has a current ratio of 27.91, a quick ratio of 27.91 and a debt-to-equity ratio of 0.05. The stock has a market cap of $8.80 billion, a price-to-earnings ratio of 2.35 and a beta of 1.24. The company has a 50-day moving average price of $11.75 and a two-hundred day moving average price of $11.21.

Roivant Sciences (NASDAQ:ROIV) last released its earnings results on Thursday, August 8th. The company reported $0.12 EPS for the quarter, beating the consensus estimate of ($0.21) by $0.33. Roivant Sciences had a net margin of 2,991.75% and a negative return on equity of 17.23%. The business had revenue of $55.10 million during the quarter, compared to analyst estimates of $30.72 million. During the same period in the prior year, the business earned ($0.38) earnings per share. The business’s quarterly revenue was up 155.1% on a year-over-year basis. Analysts forecast that Roivant Sciences Ltd. will post -1.14 EPS for the current year.

About Roivant Sciences

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.